Last reviewed · How we verify
DF289 plus DF277
DF289 plus DF277 is a fixed-dose combination targeting multiple pathways in inflammatory or metabolic disease.
At a glance
| Generic name | DF289 plus DF277 |
|---|---|
| Also known as | Antibiotic and Corticosteroid |
| Sponsor | Salvat |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information for this Salvat combination, the exact molecular targets and synergistic effects cannot be reliably specified. DF289 and DF277 are investigational compounds in phase 3 development, and their combined mechanism of action requires access to proprietary clinical trial data or company disclosures.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa (PHASE3)
- Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients (PHASE3)
- Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DF289 plus DF277 CI brief — competitive landscape report
- DF289 plus DF277 updates RSS · CI watch RSS
- Salvat portfolio CI